SUMMIT THERAPEUTICS INC. (SMMT)
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak business signals • Minimal market impact **Sentiment:** Neutral (50%) **Content type:** Business